Drugmakers see a pricing blueprint in an $850,000 gene therapy

SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.

from Reuters: Business News http://ift.tt/2r4m5ED